SRTA (Strata Critical Medical) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SRTA Strata Critical Medical Inc SRTA
68 GF Score
Price $5.04
GF Value $4.48
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strata Critical Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Strata Critical Medical is: High Risk: High uncertainty with risk-return tradeoff.

Strata Critical Medical  (NAS:SRTA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Strata Critical Medical Risk Assessment Related Terms

SRTA vs CYH, CCRN, AUNA: Risk Assessment Comparison

For the Medical Care Facilities subindustry, Strata Critical Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Strata Critical Medical Risk Assessment vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Strata Critical Medical's Risk Assessment falls into.


SRTA
68GF Score
Strata Critical Medical Inc SRTA
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Strata Critical Medical (SRTA) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued. The current stock price of $5.04 is trading 12.5% above its estimated GF Value™ of $4.48. GuruFocus considers Strata Critical Medical to be Modestly Overvalued.

Key valuation signals for SRTA:

  • Risk Assessment:
  • GF Value™: $4.48 vs. price of $5.04 (12.5% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strata Critical Medical Business Description

Address 31 Hudson Yards, 14th Floor, New York, NY, USA, 10001
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
68GF Score

Get the complete analysis for SRTA

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.04
Price
$4.48
GF Value